Comparison 1. PBM treatment versus control for non‐exudative AMD.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 BCVA at 12 months [LogMar]	2	90	Mean Difference (IV, Fixed, 95% CI)	0.02 [‐0.02, 0.05]
1.2 BCVA at 3 months [LogMar]	2	78	Mean Difference (IV, Fixed, 95% CI)	‐0.07 [‐0.13, ‐0.00]
1.3 Contrast sensitivity at 12 months Level E [18cycles/degree]	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
1.4 Self‐reported visual function	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
1.5 Health‐related quality of life EQ‐5D	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
1.6 Conversion to exudative AMD	2	96	Risk Ratio (M‐H, Fixed, 95% CI)	0.97 [0.17, 5.44]
1.7 AMD progression at 12 months	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected